submacular hemorrhage
Conditions
Interventions
Intravitreal injection group:Intravitreal injection of Conbercept (0.5mg/0.05ml) + tissue type plasminogen activator (25ug)+C3F8 gas 0.4ml
Subretinal injection group:Vitrectomy and subretinal injection of tissue type plasminogen activator (25ug), and intravitreal injection of conbercept (0.5mg/0.05ml)++C3F8 gas 0.4ml
Sponsors
Dongguan Guangming Ophthalmology Hospital
Eligibility
Sex/Gender
All
Age
45 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Age above 45 years old; 2. SMH with a duration of no more than 2 weeks from onset to surgery; 3. Diagnosed as wAMD or PCV based on fundus photography, FFA combined with ICGA examination; 4. The thickness of subretinal hemorrhage involving the macular fovea is greater than 125um (SD-OCT scan), and the diameter exceeds 1PD size.
Exclusion criteria
Exclusion criteria: 1. Subretinal hemorrhage in the macular area caused by factors other than dehumidifying age-related macular degeneration and PCV; 2. Individuals with a history of cerebral infarction, cerebral ischemia, or myocardial infarction within 6 months; 3. Those who have had previous vitrectomy surgery or macular degeneration causing scars; 4. Patients who use anticoagulants; 5. People with diabetes retinopathy, uveitis and high myopia; 6. Those who cannot maintain a face down position; 7. Patients with refractive interstitial opacity that affects fundus observation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Displacement and absorption of SMH;visual acuity;central PED thickness;Central retinal thickness;Intraocular pressure; | — |
Countries
China
Contacts
Public ContactQing Lian
Dongguan Guangming Ophthalmology Hospital
Outcome results
None listed